Skip to main content
Premium Trial:

Request an Annual Quote

EMBL Raises 10M Euros for New Technology Fund

NEW YORK, Dec. 10 – The European Molecular Biology Laboratory has raised 10 million euros ($8.9 million) for its first technology fund, which will look to invest in start up companies emerging from the research center. 

The European Molecular Biology Laboratory Enterprise Management fund, or EMBLEM, received funds from investors including  3i of the UK, BankInvest of Denmark, and Marco Polo of Spain. 

EMBL hopes to raise an additional seven million euros and to close the fund next year. 

EMBL, which has spun off such companies as Lion Bioscience, Cenix BioScience, Cellzome, and Gene Bridges, hopes that the new fund will help it to commercialize more emerging technologies. 

“With the EMBL Technology Fund we have created another vital building block necessary for the successful overall implementation of technology transfer at EMBL,” Gabor Lamm, managing director of EMBLEM, said in a statement released last week.

EMBL of Heidelberg, Germany, is a basic research institute. It receives its funding from 16 member states, including most of the EU, Switzerland, and Israel.

The Scan

Just Breathing

A new analysis suggests that most Mycobacterium tuberculosis is spread by aerosols from breathing, rather than by coughing, the New York Times reports.

Just Like This One

NPR reports that the World Health Organization has hired a South African biotech company to recreate mRNA vaccine for SARS-CoV-2 that is similar to the one developed by Moderna.

Slow Start

The Wall Street Journal reports that Biogen's Alzheimer's disease treatment had revenues for July through September that totaled $300,000.

Genome Research Papers on Cancer Chromatin, Splicing in the Thymus, Circular RNAs in Cancer

In Genome Research this week: analysis of bivalent chromatin sites, RBFOX splicing factors' role in thymic epithelial cells, and more.